<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00054600</url>
  </required_header>
  <id_info>
    <org_study_id>GvHD Prevention</org_study_id>
    <nct_id>NCT00054600</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of Photopheresis With UVADEX to Prevent Graft-versus-Host Disease</brief_title>
  <official_title>A Study of Extracorporeal Photopheresis With UVADEX in the Setting of a Standard Myeloablative Conditioning Regimen for the Prevention of Graft-versus-Host Disease in Patients Undergoing an Allogeneic Bone Marrow Transplant or Peripheral Blood Stem Cell Transplant</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mallinckrodt</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mallinckrodt</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether Extracorporeal Photopheresis with UVADEX&#xD;
      (ECP) prior to bone marrow or peripheral blood stem cell transplantation is effective in the&#xD;
      prevention of Graft-versus-Host Disease (GvHD).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Approximately 30% of HLA-identical related bone marrow graft recipients and up to 90% of&#xD;
      patients receiving bone marrow from unrelated donors develop significant acute GvHD despite&#xD;
      the use of prophylactic therapies such as cyclosporine and methotrexate. About half of these&#xD;
      patients respond to initial treatment with steroids and require no further treatment. The&#xD;
      remainder of these patients are either unresponsive to initial therapy or become&#xD;
      steroid-resistant over time. The prognosis in these cases is poor and mortality for patients&#xD;
      with steroid-resistant GvHD may be as high as 50%.&#xD;
&#xD;
      ECP is a technique in which peripheral white blood cells are exposed to a photoactivatable&#xD;
      compound (UVADEX) administered extracorporeally and ultraviolet A light. After cells are&#xD;
      reinfused into the patient, their function is altered, thereby activating mechanisms that&#xD;
      allow for further regulation of specific lymphocyte populations. ECP has shown activity in&#xD;
      several inflammatory and autoimmune diseases, including scleroderma, rheumatoid arthritis,&#xD;
      transplantation rejection, acute and chronic GvHD.&#xD;
&#xD;
      In a previous single-center, open label, single-arm study of 56 patients receiving ECP&#xD;
      treatment on two consecutive days and reduced-intensity bone-marrow conditioning prior to&#xD;
      bone marrow transplantation from matched or partially matched human donors, the incidence of&#xD;
      grade II-IV acute GvHD was less than 10%. This is in contrast to an expected incidence of&#xD;
      approximately 40%.&#xD;
&#xD;
      The purpose of this study is to determine the role of ECP, administered pre-transplant, in&#xD;
      preventing GvHD when used in conjunction with a standard myeloablative conditioning regimen.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2002</start_date>
  <completion_date>June 2004</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment>60</enrollment>
  <condition>Graft-versus-Host Disease</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methoxsalen</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Extracorporeal Photopheresis</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with a diagnosis of a malignancy of the blood (e.g. leukemia) for which&#xD;
             allogeneic bone marrow or peripheral blood stem cell transplantation is a treatment&#xD;
             option.&#xD;
&#xD;
          -  Patients who are candidates for a standard allogenic bone marrow transplant or PBSC&#xD;
             transplant.&#xD;
&#xD;
          -  Patients must have adequate renal, hepatic, pulmonary and cardiac function to enable&#xD;
             the patient to tolerate shifts in the volumes of body fluids associated with&#xD;
             extracorporeal photopheresis, as determined by the physician's clinical judgement.&#xD;
&#xD;
          -  Patients must weigh at least 40 kg (88 lbs)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who have received a prior bone marrow transplant or peripheral blood stem&#xD;
             cell transplant.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tufts New England Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kansas City Cancer Center</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Transplant</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Brisbane Hospital</name>
      <address>
        <city>Brisbane</city>
        <zip>4006</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peter MacCallum Cancer Institute</name>
      <address>
        <city>East Melbourne</city>
        <zip>8006</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alfred Hospital</name>
      <address>
        <city>Melbourne</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Melbourne Hospital</name>
      <address>
        <city>Parkville</city>
        <zip>3050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Vincent's Hospital</name>
      <address>
        <city>Sydney</city>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Azevedo Carvalho</name>
      <address>
        <city>Jau</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cancer Institute</name>
      <address>
        <city>Rio de Janeiro</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hemocentro</name>
      <address>
        <city>Sao Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ludwig-Maximiliano Universitaet Muenchen</name>
      <address>
        <city>Munchen</city>
        <zip>D-81377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Careggi Hospital</name>
      <address>
        <city>Florence</city>
        <zip>1-50134</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Martino Hospital</name>
      <address>
        <city>Genova</city>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Portugues de Oncologia de Francisco Gentil</name>
      <address>
        <city>Lisbon</city>
        <zip>1099-023</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cancer Institute</name>
      <address>
        <city>Bratislava</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ankara University Medical School</name>
      <address>
        <city>Ankara</city>
        <zip>6100</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hammersmith Hospital</name>
      <address>
        <city>London</city>
        <zip>W12 0NN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Brazil</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Portugal</country>
    <country>Slovakia</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Shlomchik WD, Couzens MS, Tang CB, McNiff J, Robert ME, Liu J, Shlomchik MJ, Emerson SG. Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science. 1999 Jul 16;285(5426):412-5.</citation>
    <PMID>10411505</PMID>
  </reference>
  <verification_date>August 2017</verification_date>
  <study_first_submitted>February 5, 2003</study_first_submitted>
  <study_first_submitted_qc>February 5, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 6, 2003</study_first_posted>
  <last_update_submitted>August 14, 2017</last_update_submitted>
  <last_update_submitted_qc>August 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 16, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Extracorporeal Photopheresis</keyword>
  <keyword>Graft-versus-Host Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Graft vs Host Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methoxsalen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

